Early results from two MD Anderson studies show promising responses to neoadjuvant (pre-surgical) checkpoint inhibitors in patients with advanced, resectable cutaneous squamous cell carcinoma of the head and neck (CSCC-HN), a type of skin cancer, and hepatocellular carcinoma (HCC), a type of liver cancer. Neither disease currently has an effective FDA-approved chemotherapy or can be cured through surgery alone. Initial results from both...
Jan Barbo likely got hepatitis C from a blood transfusion. Almost 50 years ago, she suffered an ectopic pregnancy when a fertilized egg attached...
The cost of treating people infected with the hepatitis C virus (HCV) with newly approved therapies will likely place a tremendous economic...
Effective new drugs and screening would make hepatitis C a rare disease by 2036, according to a computer simulation conducted by MD Anderson Cancer Center and the University of Pittsburgh Graduate School of Public Health. The results of the simulation were reported in the Aug. 5 edition of the journal Annals of Internal Medicine.
“Hepatitis C (HCV) is the leading cause of liver cancer and accounts for more...
